The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
复制标题
DOI：
10.1016/j.vaccine.2008.03.072
复制
发表时间：
2008-09
期刊：
影响因子：
5.5
通讯作者：
Yi-ping Xing;Zu-hu Huang;Yan Lin;Jun Li;Te-Hui Chou;Shan Lu;Shixia Wang
中科院分区：
文献类型：
--
作者：
Yi-ping Xing;Zu-hu Huang;Yan Lin;Jun Li;Te-Hui Chou;Shan Lu;Shixia Wang
乙肝病毒感染是一种世界性的重大传染病，具有严重的长期发病率和死亡率。有限的药物治疗选择不能控制活动性和持续性乙肝病毒感染者的疾病进展。控制小瓶感染程度的免疫疗法是解决这一挑战的一种可能的替代方案。HBVDNA疫苗具有很强的诱导细胞免疫反应的能力，提供了一个有吸引力的选择。乙肝病毒表面蛋白在病毒免疫中起重要作用。慢性乙肝患者重新建立抗S免疫，将给患者带来明显的益处。此前的研究表明，乙肝病毒S DNA疫苗在多项动物研究中具有免疫原性。在本研究中，我们进一步研究了糖基化对S DNA疫苗表达和免疫原性的影响。我们的结果表明，S蛋白两个潜在的N-连接糖基化位点的去糖基化导致了S特异性细胞免疫应答的显著降低，但不影响抗S抗体的应答。这一发现为S DNA疫苗的研制提供了重要的方向，以诱导最佳且平衡的抗体和细胞免疫反应来治疗乙肝病毒慢性感染者。
Hepatitis B Virus (HBV) infection remains a major worldwide infectious disease with serious long-term morbidity and mortality. The limited selections of drug treatment are not able to control the progress of disease in people with active and persistent HBV infection. Immunotherapy to control the degree of vial infection is one possible alternative solution to this challenge. HBV DNA vaccines, with their strong ability to induce cell-mediated immune responses, offer an attractive option. HBV surface protein is important in the viral immunity. Re-establishing anti-S immunity in chronic HBV infected patients will bring significant benefit to the patients. Previous studies have shown that HBV S DNA vaccines are immunogenic in a number of animal studies. In the current study, we further investigated the effect glycosylation to the expression and immunogenicity of S DNA vaccines. Our results demonstrated that deglycosylation at the two potential N-linked glycosylation sites in S protein resulted in significant decrease of S-specific cell-mediated immune responses, but did not affect the anti-S antibody responses. This finding provides important direction to the development of S DNA vaccines to elicit the optimal and balanced antibody and cell-mediated immune responses to treat people with HBV chronic infections.